Clinical Trial Supply Costs: Where the Money Actually Goes (and How to Stop the Leaks)

Ask a study team where the supply budget goes and you'll hear about drug manufacturing and shipping. Ask the invoices, and a different story emerges: the big money moves through overage that gets destroyed, comparator purchases nobody scrutinized, expedited shipments covering planning gaps, and end-of-study returns and destruction that everyone forgot to budget. Clinical supply is one of the least examined major line items in development — which is precisely why it's one of the most compressible. Here's where the money actually goes, and which levers genuinely move it.

What are the real cost drivers in clinical supply?

Seven categories account for most of the spend:

• Drug substance and manufacturing — the obvious one, made worse by the industry's habit of producing far more than patients will ever take. Overage beyond half of manufactured supply is commonly reported, and every wasted kit carries manufacturing, packaging, shipping, storage, and destruction cost stacked on top of each other.
• Comparators and co-medications — often the most expensive material in the study when the control arm uses a commercial biologic. Sourcing route, country of purchase, and negotiation discipline swing this line dramatically.
• Packaging and labeling — driven less by unit costs than by rework: relabeling campaigns after protocol or expiry changes are pure leak.
• Logistics and cold chain — with expedited and hand-carry shipments as the tell-tale symptom of forecasting and buffer problems upstream. A supply chain that routinely pays for speed is paying for earlier mistakes.
• Depot network and storage — every additional depot adds fixed cost; networks are often built for a footprint the enrollment never justified.
• Excursions and losses — each lost shipment is the full stack of costs plus replacement plus, sometimes, a patient impact. A weak excursion process turns recoverable events into write-offs.
• Returns, reconciliation, and destruction — the forgotten end of the chain, routinely under-budgeted and painfully manual.

Why does overage dominate the waste conversation?

Because it compounds. Overage isn't one decision — it's a pyramid of safety margins stacked by people who never see each other's buffers: manufacturing adds yield margin, the forecast adds enrollment optimism, the supply plan adds safety stock, the IRT settings add site buffers, and expiry takes its cut of whatever survives. Each margin is individually defensible; the stack is not. The remedy is equally structural: model the whole chain's service level once, centrally — a simulation answering "how much total buffer buys 99% patient coverage?" — and allocate that buffer deliberately, instead of letting every layer self-insure.

Which levers actually cut costs without adding risk?

Four have outsized returns:

1. Demand-driven supply management. Replace set-and-forget plans with monthly forecast-versus-actual reviews and IRT settings tuned to real enrollment. This is the overage lever.
2. Comparator strategy, early. Sourcing route (central vs. local), country pricing differences, pack-size fit to dosing, and waste-aware kit design — decided before the first purchase order, when the leverage exists.
3. Postponement. Late-stage labeling and late kit assignment keep inventory generic and reusable across countries and arms — cutting both overage and amendment losses.
4. Network right-sizing. Depots, shipping lanes, and shipper choices matched to the actual footprint and revisited as the study evolves — including closing what start-up optimism opened.

And one honest anti-lever: cutting patient-facing buffers to save money. A stock-out costs more than it saves — in deviations, site trust, and timeline — every single time.

How should supply costs be budgeted and governed?

Three practices distinguish programs that control this spend. Budget the whole lifecycle — including returns, reconciliation, destruction, and a realistic amendment allowance, the lines that always surprise. Track cost per patient dosed, not just total spend — it's the metric that exposes waste and survives enrollment changes. Give supply a seat when protocol decisions are made — visit schedules, dosing flexibility, and country lists are the biggest supply cost decisions in any study, and they're usually made without a supply voice in the room. As we argued in our board-metrics post, waste that nobody surfaces is waste that never shrinks.